4 recruiting, 1 active not recruiting. 3 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow HGG: new trials by email Literature Review of HGG trials Research Report on HGG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma NRG-103 - HGG, High Grade Glioma (III or IV) | Phase 1 | Recruiting | Neuregen Therapeutics Co., Ltd. | 24 | 2026-07-09 | 2026-07-17 |
| Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) Nivolumab, Nivolumab-IRDye800 - Brain Cancer, HGG | Early Phase 1 | Recruiting | Eben Rosenthal | 38 | 2026-03-27 | 2026-07-01 |
| Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy Focused Ultrasound Next Generation Dome Helmet, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension - GBM, Glioblastoma Multiforme (GBM) | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-06-04 | 2025-09-17 |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations Plixorafenib - Cancer Harboring BRAF Alterations, HGG | Phase 2 | Recruiting | Fore Biotherapeutics | 254 | 2023-02-21 | 2026-07-27 |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors PF-07799544, PF-07799933 - Melanoma, Glioma | Phase 1 | Active not recruiting | Pfizer | 148 | 2022-11-30 | 2026-09-01 |
Glioma (5) · Brain Neoplasms (3) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1) · Thyroid Neoplasms (1)
Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Neoplasms (4) · Neoplasms by Site (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Central Nervous System Neoplasms (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2)
Eben Rosenthal (1) · Fore Biotherapeutics (1) · Neuregen Therapeutics Co., Ltd. (1) · Pfizer (1) · Sunnybrook Health Sciences Centre (1)
Canada (3) · United States (3) · Australia (2) · China (2) · Brazil (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · South Korea (1) · Spain (1) · Sweden (1)
Nir Lipsman (1) · Patrick Kelly, MD (1)